Search

The clinical course of lung transplantation (LT) is diverse: some patients present chronic lung allograft dysfunction (CLAD) and progressive decline in pulmonary function, but others maintain normal spirometric values and active lives., Objectives: The aim of this study was to elucidate whether long-term LT survivors with normal spirometry achieve normal exercise capacity, and to identify predictive factors of exercise capacity., Methods: This was a cross-sectional multicentre study, where bilateral LT recipients who survived at least 10 years after LT, with normal spirometry, no diagnosis of CLAD and modified Medical Research Council dyspnoea degree ≤2 underwent cardiopulmonary exercise testing (CPET)., Results: 28 LT recipients were included with a mean±sd age of 48.7±13.6 years. Oxygen uptake ( V' O 2 ) had a mean±sd value of 21.49±6.68 mL·kg -1 ·min -1 (75.24±15.6%) and the anaerobic threshold was reached at 48.6±10.1% of the V' O 2 max predicted. The mean±sd heart rate reserve at peak exercise was 17.56±13.6%. The oxygen pulse increased during exercise and was within normal values at 90.5±19.4%. The respiratory exchange ratio exceeded 1.19 at maximum exercise. The median (25-75 th percentile) EuroQol-5D score was 1 (0.95-1), indicating a good quality of life. The median (25-75 th percentile) International Physical Activity Questionnaire score was 5497 (4007-9832) MET-min·week -1 with 89% of patients reporting more than 1500 MET-min·week -1 . In the multivariate regression models, age, sex and diffusing capacity of the lung for carbon monoxide remained significantly associated with V' O 2 max (mL·kg -1 ·min -1 ); haemoglobin and forced expiratory volume in 1 s were significantly associated with maximum work rate (watts), after adjusting for confounders., Conclusion: We report for the first time near-normal peak V' O 2 values during CPET and normal exercise capacity in long-term LT recipients without CLAD., Competing Interests: Conflict of interest: B. Saez-Gimenez reports lecture fees from GlaxoSmithKline, and travel grants from Actelion Pharmaceuticals, Bial, Mundipharma, Novartis and Astellas Pharma, during the conduct of the study. Conflict of interest: M. Barrecheguren has nothing to disclose. Conflict of interest: M.A. Ramon has nothing to disclose. Conflict of interest: A. Gomez-Garrido has nothing to disclose. Conflict of interest: C. Bravo has nothing to disclose. Conflict of interest: V. Monforte has nothing to disclose. Conflict of interest: M. López-Meseguer has nothing to disclose. Conflict of interest: C. Berastegui has nothing to disclose. Conflict of interest: E. Revilla has nothing to disclose. Conflict of interest: C. Romero has nothing to disclose. Conflict of interest: R. Laporta has nothing to disclose. Conflict of interest: S. Fernández-Rozas has nothing to disclose. Conflict of interest: J. Redel-Montero has nothing to disclose. Conflict of interest: A. Solé has nothing to disclose. Conflict of interest: M. de la Torre has nothing to disclose. Conflict of interest: L. Puente has nothing to disclose. Conflict of interest: A. Roman has nothing to disclose. Conflict of interest: S. Gómez-Ollés reports travel grants from Teva and Actelion Pharmaceuticals during the conduct of the study. Conflict of interest: I. Ojanguren reports personal fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, grants and personal fees from Mindipharma, personal fees from Novartis and Teva, grants from Menarini, and personal fees from MSD, during the conduct of the study., (Copyright ©ERS 2021.)